These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25326871)

  • 1. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.
    Diels J; Hamberg P; Ford D; Price PW; Spencer M; Dass RN
    Qual Life Res; 2015 Mar; 24(3):591-8. PubMed ID: 25326871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
    Skaltsa K; Longworth L; Ivanescu C; Phung D; Holmstrom S
    Value Health; 2014 Mar; 17(2):238-44. PubMed ID: 24636382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
    Yang Q; Yu XX; Zhang W; Li H
    Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).
    Badia X; Roset M; Valassi E; Franz H; Forsythe A; Webb SM
    Qual Life Res; 2013 Dec; 22(10):2941-50. PubMed ID: 23539468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
    Wu EQ; Mulani P; Farrell MH; Sleep D
    Value Health; 2007; 10(5):408-14. PubMed ID: 17888106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
    Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
    Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
    Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
    Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.
    Murasawa H; Sugiyama T; Matsuoka Y; Okabe T; Hino A; Tanaka N; Sugimoto M; Oyama M; Fujimoto K; Horie S; Noto S; Shimozuma K
    Qual Life Res; 2019 Sep; 28(9):2383-2391. PubMed ID: 31025290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
    BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
    Lloyd AJ; Kerr C; Penton J; Knerer G
    Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study.
    Doherty MK; Leung Y; Su J; Naik H; Patel D; Eng L; Kong QQ; Mohsin F; Brown MC; Espin-Garcia O; Vennettilli A; Renouf DJ; Faluyi OO; Knox JJ; MacKay H; Wong R; Howell D; Mittmann N; Darling GE; Cella D; Xu W; Liu G
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29905764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
    Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B
    Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
    Jiang L; Zhou H; Yang Q; Luo X; Huang D
    Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
    Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
    J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the FACT-G to EQ-5D-3L utility index in cancer with the Chinese values set.
    He Z; Liang W; Xu W; Huang W; Wang X; Huang K; Yang L
    Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1103-1116. PubMed ID: 35711123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.